What side effects are associated with this type of intervention?

Common treatments for Substance Use Disorders, such as Motivational Interviewing (MI), Cognitive-Behavioral Therapy (CBT), and contingency management, generally have minimal physical side effects as they are primarily psychosocial interventions. However, patients may experience emotional discomfort as they confront and work through their substance use issues. This can include increased anxiety, stress, or emotional distress during therapy sessions. Additionally, the process of behavior change can be challenging and may lead to temporary increases in cravings or withdrawal symptoms as patients adjust to new coping strategies and reduce substance use.

What prior FDA approvals exist?

The FDA has approved several medications for the treatment of Substance Use Disorders that align with the principles of Motivational Interviewing by enhancing motivation and engagement. For opioid use disorder, medications like methadone, buprenorphine, and naltrexone are commonly used. For alcohol use disorder, disulfiram, naltrexone, and acamprosate have been approved. These medications are often used in conjunction with behavioral therapies, including Cognitive-Behavioral Therapy (CBT) and Motivational Interviewing, to address ambivalence and foster intrinsic motivation for change, thereby improving treatment outcomes.

What other types of research exist?

Promising novel alternatives to Motivational Interviewing at Intake for SUD patients include: 1) Digital self-help interventions, such as internet-based guided self-help and smartphone applications, which have shown efficacy in other behavioral disorders and can enhance engagement through accessibility and continuous support. 2) Telephone-delivered peer interventions, which provide support and encouragement from individuals with lived experience, fostering a sense of community and motivation. 3) Behavioral medical management, which combines medication adherence monitoring with structured behavioral support, education, and encouragement to attend mutual help groups, enhancing overall treatment engagement.

← Back to Search

Motivational Interviewing for Substance Use Disorders

N/A

Recruiting

Led By Margo Hurlocker, PhD

Research Sponsored by University of New Mexico

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 1 year

Awards & highlights

Study Summary

This trial will test whether using Motivational Interviewing at Intake (MII) with adults seeking outpatient addiction treatment leads to better engagement with treatment and understand why this is the case. Personnel feedback will be gathered on whether MII is feasible to implement into standard practice.

Who is the study for?

This trial is for English-speaking adults seeking outpatient treatment for alcohol or drug use, who are willing to follow study procedures and have given informed consent. It's also open to staff at the treatment programs. Participants must not be physically dependent on substances at the time of intake.Check my eligibility

What is being tested?

The study compares two approaches: usual intake procedures versus Motivational Interviewing at Intake (MII) to see which is more effective in engaging clients in addiction treatment. The trial will also assess how easy it is to integrate MII into regular practice.See study design

What are the potential side effects?

Since this trial involves counseling techniques rather than medication, traditional side effects are not expected. However, participants may experience emotional discomfort discussing their substance use during motivational interviewing sessions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants who attended the first outpatient treatment program session based on electronic medical record review

Number of participants who completed the three-month outpatient treatment program based on electronic medical record review

Number of treatment sessions attended during the three-month outpatient treatment program based on electronic medical record review

Secondary outcome measures

Change from baseline in client readiness to enter treatment on the University of Rhode Island Change Assessment Scale (URICA) at 1 hour post-intake

Score on therapeutic alliance on the Working Alliance Inventory (WAI) at 1-hour post-intake

Other outcome measures

Change from baseline in organizational capability to change on the Change Process Capability Questionnaire (CPCQ) at Year 1

Change from baseline in organizational readiness to change on the Readiness for Organizational Change (ROC) at 1 year

Change from baseline in organizational readiness to change on the Texas Christian University-Organizational Readiness to Change (TCU-ORC) at 1 year

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Motivational Interviewing at Intake (MII)Experimental Treatment1 Intervention

Clients allocated to the MII condition will receive a 90-minute pure Motivational Interviewing (MI) session.

Group II: Intake as Usual (IAU)Active Control1 Intervention

Clients allocated to the IAU condition will receive the 90-minute standard assessment that is delivered to all clients entering intensive outpatient program (IOP)/outpatient program (OP).

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for Substance Use Disorders (SUDs) include Cognitive Behavioral Therapy (CBT), Motivational Interviewing (MI), and Contingency Management (CM). CBT helps patients identify and modify distorted thinking patterns and behaviors that contribute to substance use, promoting healthier coping strategies. MI enhances client engagement by addressing ambivalence and fostering intrinsic motivation for change, making it particularly effective at the intake stage. CM uses positive reinforcement, such as vouchers or rewards, to encourage abstinence and adherence to treatment. These mechanisms are crucial as they address the psychological and behavioral aspects of addiction, improving treatment retention and outcomes for SUD patients.

Self-awareness deficits associated with lower treatment motivation in cocaine addiction.A review of psychosocial interventions for amphetamine use.

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH

2,496 Previous Clinical Trials

2,623,755 Total Patients Enrolled

University of New MexicoLead Sponsor

374 Previous Clinical Trials

3,528,491 Total Patients Enrolled

Margo Hurlocker, PhDPrincipal InvestigatorUniversity of New Mexico

Media Library

Intake as Usual (IAU) Clinical Trial Eligibility Overview. Trial Name: NCT05489068 — N/A

Substance Use Disorders Research Study Groups: Intake as Usual (IAU), Motivational Interviewing at Intake (MII)

Substance Use Disorders Clinical Trial 2023: Intake as Usual (IAU) Highlights & Side Effects. Trial Name: NCT05489068 — N/A

Intake as Usual (IAU) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05489068 — N/A

~15 spots leftby Oct 2024

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.